Keywords: incretin, nicotinamide adenine dinucleotide, nicotinamide phosphoribosyltransferase, postprandial glucose metabolism, intestinal homeostasis 1
Researchers should always verify local regulations and sourcing standards before obtaining research compounds
Semaglutide is a GLP-1 receptor agonist that mimics the natural incretin hormone to reduce appetite, slow gastric emptying, and improve blood sugar regulation
Even with bacteriostatic water, overwhelming contamination can overpower the preservative
This triple mechanism distinguishes it from existing approved agents semaglutide, for example, acts on the GLP-1 receptor only, whilst tirzepatide is a dual GIP/GLP-1 receptor agonist and is being investigated to determine whether broader receptor engagement offers additional metabolic benefit
In the UK and Ireland, both peptides can be legally purchased for research use through verified suppliers